Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia

Summary

Atavistik Bio joined the Cure HHT Clinical Trial Network to advance development of ATV-1601, an oral AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia. This partnership supports the clinical development of the investigational rare disease therapy.